CERS
Cerus CorporationNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$367.05M
P/E Ratio
—
EPS
$-0.08
Beta
1.63
52W High
$2.96
52W Low
$1.15
50-Day MA
$2.11
200-Day MA
$1.73
Dividend Yield
—
Profit Margin
-7.58%
Forward P/E
—
PEG Ratio
0.00
About Cerus Corporation
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Fundamentals
| Revenue (TTM) | $206.13M |
| Gross Profit (TTM) | $112.29M |
| EBITDA | $-7.25M |
| Operating Margin | -1.11% |
| Return on Equity | -25.70% |
| Return on Assets | -2.57% |
| Revenue/Share (TTM) | $1.08 |
| Book Value | $0.33 |
| Price-to-Book | 5.76 |
| Price-to-Sales (TTM) | 1.78 |
| EV/Revenue | 1.863 |
| EV/EBITDA | -13.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 13.70% |
| Shares Outstanding | $192.17M |
| Float | $164.08M |
| % Insiders | 4.43% |
| % Institutions | 77.61% |
Historical Volatility
HV 10-Day
46.30%
HV 20-Day
51.23%
HV 30-Day
81.29%
HV 60-Day
76.34%
HV Rank
84.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($5.00 target)
3
Buy1
HoldData last updated: 4/10/2026